CellEDIT - CRISPR-Edited MDA MB 231 Cell Line
We provide you with a custom and high-quality engineered MDA MB 231 cell line to support your research.
We'll handle the CRISPR editing of your MDA MB 231 cell line, so you can concentrate on your experiment.
The MDA MB 231 cell line was derived from a human breast adenocarcinoma. With their nature and hormone responsiveness, MDA MB 231 cells are widely used in biological research and industrial applications.
MDA MB 231 Cell Line Information
Organism
Human
Tissue Type
Breast - Mammary Gland
Cell Type
Epithelial
Disease
Adenocarcinoma
Donor Information
Age
51
Gender
Female
Ethnicity
Unknown
MDA MB 231 Cell Line Applications
Tumor Biology: MDA MB 231 cells are used as a model for studying triple negative breast cancers (TNBC) a very aggressive subtype of this disease.
Drug Resistance: Investigating the development of resistance to chemotherapy and other treatments.
Screening Anti-Cancer Drugs: Evaluating the efficacy of new anti-cancer compounds and therapeutic agents.
Mechanistic Studies: Unraveling the molecular and cellular mechanisms of drug actions in triple negative breast cancers.
Drug Discovery: Using MDA MB cell lines in automated platforms for high throughput screening of large compound libraries.
Related Case Studies
Elevate your research with CellEDIT's expertise. MDA MB 231 cell lines contribute significantly to our understanding of breast cancer and the development of new therapeutic strategies. With the CellEDIT workflow and within 10 weeks, we can design for you custom CRISPR-edited MDA MB 231 cell lines through direct intra-nuclear injection, suited for your project needs.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Discover how the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Explore how
the CellEDIT workflow was used to produce
3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT,
we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell LineCRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.
Case Study - Streamlined U2OS Cell Line Modification with the CellEDIT Service Workflow, featuring our CellEDIT Customer: Dr. Kanstantsin Siniuk.